Proton pump inhibitors are prescribed to reduce stomach acid. For some patients, they make symptoms worse. When reflux is caused by insufficient acid rather than excess acid, suppressing production further can intensify bloating, SIBO, nutrient deficiencies, and the reflux itself. A direct measurement of gastric acid secretion can determine whether acid suppression is helping or harming.
Proton pump inhibitors were designed for short-term use. The original clinical trials that led to their approval tested them over periods of four to eight weeks for acute conditions like duodenal ulcers and erosive esophagitis. That was the intended duration. In clinical practice, something different happened. Prescriptions that were meant to last a month became permanent.
A 2019 study published in the British Journal of General Practice found that approximately 50% of patients on long-term PPIs had no documented indication for ongoing use. A separate analysis in Alimentary Pharmacology and Therapeutics estimated that 25-70% of PPI prescriptions lack an appropriate clinical basis. The drugs work well for what they were designed to treat. The problem is that they are now prescribed reflexively for symptoms they may not be treating correctly.
Heartburn feels the same whether it is caused by too much acid or too little. The burning sensation is produced by stomach contents contacting the esophageal mucosa. It does not tell you whether the refluxate is highly acidic, mildly acidic, or even alkaline. The symptom is identical. The cause may be opposite.
When stomach acid is low, food sits in the stomach longer than it should. Bacterial fermentation increases. Gas builds. The stomach distends. Pressure rises against the lower esophageal sphincter. Contents reflux upward. The patient reports heartburn. The doctor prescribes a PPI. The acid level, already insufficient, drops further. Gastric emptying slows more. Fermentation increases. The cycle deepens.
This is not a rare scenario. Clinicians in functional and integrative medicine see it routinely. The patient has been on a PPI for years with unchanged or worsening symptoms. They have tried multiple PPIs at escalating doses. They have been told they have refractory GERD. What they may actually have is insufficient acid being suppressed into further insufficiency.
Gastric acid does more than digest food. It is the primary antimicrobial barrier between what you swallow and your small intestine. It activates pepsin for protein breakdown. It releases nutrients from food for absorption. It triggers the hormonal cascade that coordinates downstream digestion. When you suppress acid for months or years, all of these functions are impaired.
A meta-analysis by Lo and Chan (2013, Clinical Gastroenterology and Hepatology) found a statistically significant association between PPI use and small intestinal bacterial overgrowth. The mechanism is straightforward. Less acid means more bacteria survive the stomach and reach the small intestine. If motility is also impaired, those bacteria colonize and proliferate.
The FDA has issued safety communications about associations between long-term PPI use and hypomagnesemia, B12 deficiency, increased fracture risk, C. difficile infection, and community-acquired pneumonia. The American Gastroenterological Association has acknowledged these risks in updated guidelines. None of this means PPIs are bad drugs. It means they are being used beyond their intended scope in a significant number of patients.
Reimer and colleagues demonstrated in a 2009 Gastroenterology study that healthy volunteers with no prior acid-related symptoms developed dyspepsia, heartburn, and acid regurgitation after discontinuing just eight weeks of PPI therapy. The symptoms were caused by rebound acid hypersecretion. Parietal cells that had been suppressed overcompensated when released. The symptoms felt exactly like the original problem returning.
In clinical practice, this creates a self-reinforcing cycle. The PPI is prescribed. Stopping it causes rebound symptoms. The rebound is interpreted as proof that continued suppression is necessary. The prescription continues. Neither the patient nor the prescriber knows whether the original problem was excess acid, because nobody measured it.
The Heidelberg pH Capsule measures gastric acid secretion and reacidification capacity in real time. The bicarbonate challenge protocol answers the question that no empirical PPI trial can answer: is this stomach producing too much acid, normal acid, or too little acid?
For patients who have been on PPIs for months or years without improvement, this data changes the conversation. If acid output is already low, continued suppression is not just unnecessary. It may be contributing to the very symptoms it was prescribed to treat. If acid output is genuinely elevated, the PPI is justified and the patient can continue with confidence. Either way, the decision is based on evidence rather than assumption.
If you have been on a PPI for more than a few months and your symptoms have not resolved, this does not necessarily mean the medication is wrong for you. It means the question has not been answered. A professional gastric acid assessment can provide the data you and your clinician need to make an informed decision about ongoing therapy.
Take our 2-minute self-assessment quiz to see whether gastric acid assessment may be relevant to your situation. Or find a practitioner near you who offers the Heidelberg test.
The Heidelberg pH Capsule is a Class I medical device, 510(k)-exempt, listed with the U.S. Food and Drug Administration under 21 CFR §876.1400. Listing of a device does not denote FDA approval, clearance, or endorsement.